Cenna Biosciences Inc.
Putting a new spin on amyloid beta target in AD
This article was originally published in Start Up
Executive Summary
Cenna Biosciences thinks it has come up with a way to target amyloid beta that will succeed where other companies have failed in Alzheimer’s disease. The San Diego-based start-up has developed technology that creates peptide drug candidates that bind the amyloid precursor protein, to prevent amyloid beta buildup in the first place.
You may also be interested in...
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Can-Fite Plans Phase III For Namodenoson, Despite Liver Cancer Trial Failure
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.